Sufentanil Citrate is named as an intervention in 4 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Shiyou Wei (1). The most-studied condition is Cough.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Recovery in Patients Undergoing Major Abdominal Surgery
NCT07651722 · ClinicalTrials.gov ↗ · Postoperative Pain, Postoperative Ileus
|
Not applicable | Recruiting | Tianjin First Central Hospital | China |
|
the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery
NCT06530563 · ClinicalTrials.gov ↗ · Acute Pain, Opioid Analgesic Adverse Reaction
|
Phase 4 | Not yet open | Xiangya Hospital of Central South University | China |
|
90% Effective Infusion Time of Sufentanil to Prevent Induction Cough: A Biased Coin Sequential Study
NCT07778953 · ClinicalTrials.gov ↗ · Cough
|
Not applicable | Not yet open | Shiyou Wei | China |
|
Oxycodone and Sufentanil for Analgesia in Hip Surgery
NCT03685188 · ClinicalTrials.gov ↗ · Analgesia, Patient-Controlled
|
Phase 4 | By invitation | West China Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shiyou Wei | 1 |
| Tianjin First Central Hospital | 1 |
| Xiangya Hospital of Central South University | 1 |
| West China Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Sufentanil Citrate as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 4 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shiyou Wei (1), Tianjin First Central Hospital (1), Xiangya Hospital of Central South University (1) and West China Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sufentanil Citrate works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sufentanil Citrate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sufentanil Citrate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.